Kezar Life Sciences, Inc. (KZR)
May 11, 2026 - KZR was delisted (reason: acquired by AUPH)
7.29
0.00 (0.00%)
Inactive · Last trade price on May 8, 2026
Kezar Life Sciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 66.23 | 71.88 | 41.75 | 35.49 | 40.46 | 62.88 |
Short-Term Investments | - | - | 90.5 | 165.88 | 236.11 | 145.47 |
Cash & Short-Term Investments | 66.23 | 71.88 | 132.25 | 201.37 | 276.56 | 208.36 |
Cash Growth | -42.09% | -45.65% | -34.33% | -27.19% | 32.73% | 48.35% |
Other Current Assets | 1.33 | 3.85 | 5.24 | 5.58 | 9.16 | 3.3 |
Total Current Assets | 67.56 | 75.73 | 137.49 | 206.95 | 285.72 | 211.65 |
Net Property, Plant & Equipment | 0.44 | 0.92 | 4.78 | 8.69 | 13.17 | 6 |
Other Long-Term Assets | - | - | 2.42 | 5.6 | 0.67 | 0.28 |
Total Assets | 68 | 76.65 | 144.68 | 221.24 | 299.57 | 217.93 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.27 | 0.51 | 3.65 | 8.25 | 2.48 | 2.03 |
Accrued Expenses | 1.14 | 3.74 | 7.94 | 6.48 | 5.95 | 4.99 |
Short-Term Debt | - | - | 5.22 | - | - | - |
Current Portion of Leases | 1.35 | 2.33 | 3.53 | 3.01 | 2.57 | 1.2 |
Other Current Liabilities | 1.14 | 3.74 | 7.94 | 6.48 | 5.95 | 4.99 |
Total Current Liabilities | 2.76 | 6.57 | 20.33 | 17.74 | 11 | 8.21 |
Long-Term Debt | - | - | 5.11 | 10.07 | 9.83 | 9.62 |
Long-Term Leases | - | - | 2.33 | 5.85 | 8.87 | 3.22 |
Total Long-Term Liabilities | - | - | 7.44 | 15.92 | 18.7 | 12.85 |
Total Liabilities | 2.76 | 6.57 | 27.77 | 33.67 | 29.7 | 21.06 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.07 | 0.06 |
Additional Paid-in Capital | 561.52 | 560.6 | 551.57 | 538.46 | 519.62 | 377.77 |
Accumulated Other Comprehensive Income | - | - | -0.16 | -0.13 | -0.92 | -0.29 |
Retained Earnings | -496.29 | -490.53 | -434.5 | -350.76 | -248.89 | -180.65 |
Shareholders' Equity | 65.24 | 70.07 | 116.92 | 187.57 | 269.87 | 196.88 |
Total Liabilities & Equity | 68 | 76.65 | 144.68 | 221.24 | 299.57 | 217.93 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.35 | 2.33 | 16.18 | 18.93 | 21.26 | 14.04 |
Net Cash (Debt) | 64.88 | 69.55 | 116.07 | 182.44 | 255.3 | 194.31 |
Net Cash Growth | -35.29% | -40.08% | -36.38% | -28.54% | 31.39% | 43.95% |
Net Cash Per Share | 8.85 | 9.51 | 15.92 | 25.14 | 37.90 | 36.83 |
Book Value | 65.24 | 70.07 | 116.92 | 187.57 | 269.87 | 196.88 |
Book Value Per Share | 8.90 | 9.58 | 16.04 | 25.85 | 40.06 | 37.32 |
Tangible Book Value | 65.24 | 70.07 | 116.92 | 187.57 | 269.87 | 196.88 |
Tangible Book Value Per Share | 8.90 | 9.58 | 16.04 | 25.85 | 40.06 | 37.32 |